Clinical Trial Update: A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400) [Phase 2]

View source ↗

Summary

A Phase II study evaluating pegylated interferon alfa-2b as adjuvant treatment for melanoma in Russia has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2017-04-11